Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.EVFM · Entity 8607 | CFO | January 12, 2024 | January 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date January 12, 2024 · Filed January 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-12 transaction · row 1
1 source rowRow 1 · 2024-01-12 · Sale · Disposed 104 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2024 Filed Jan 12, 2024 22:13 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | SaleCommon Stock | 104 | $0.04 | $4.00 |
DisclosureSEC source: 0001493152-24-002231 · ownership.xml · nonDerivative · entry 1 Zhang Yan · CIK 0001975257 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.